



VIA SEDAR

December 23, 2022

Nova Scotia Securities Commission
British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Manitoba Securities Commission
Ontario Securities Commission
Autorité des marchés financiers
Financial and Consumer Services Commission (New Brunswick)
Office of the Superintendent of Securities, Prince Edward Island
Office of the Superintendent of Securities, Newfoundland and Labrador

Dear Sirs/Mesdames:

Re: Algernon Pharmaceuticals Inc.

In connection with the Prospectus Supplement of Algernon Pharmaceuticals Inc. dated December 23, 2022, we consent to the reference to our name under the heading “Legal Matters” and “Interests of Experts” and the reference to our name and opinion under the heading “Eligibility For Investment” in the Prospectus Supplement.

We have read the Prospectus Supplement and have no reason to believe that there are any misrepresentations in the information contained therein that is derived from our opinion referred to therein or that is within our knowledge as a result of the services that we performed in connection with such opinion.

Yours truly,

“McMillan LLP”